Tg Therapeutics (TGTX) Free Cash Flow (2011 - 2026)

Tg Therapeutics' Free Cash Flow history runs 16 years deep, the most recent figure standing at -$17.9 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 37.56% year-over-year to -$17.9 million; the TTM figure through Mar 2026 stood at -$14.2 million (up 76.77% YoY), while the FY2025 annual figure was -$25.0 million, up 38.4% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$17.9 million, down from $19.6 million in the prior quarter.
• The five-year high for Free Cash Flow was $83.7 million in Q3 2023, with the low at -$68.7 million in Q1 2022.
• The 5-year median for Free Cash Flow is -$23.2 million (2025), against an average of -$17.1 million.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow surged 342.63% in 2023, then sank 250.19% in 2025.
• Tg Therapeutics' Free Cash Flow stood at -$23.9 million in 2022, then surged by 44.67% to -$13.2 million in 2023, then sank by 94.26% to -$25.7 million in 2024, then jumped by 176.35% to $19.6 million in 2025, then tumbled by 191.59% to -$17.9 million in 2026.
• Business Quant data shows TGTX's Free Cash Flow at -$17.9 million in Q1 2026, $19.6 million in Q4 2025, and -$23.2 million in Q3 2025.